Coloplast publishes 2025/26 annual report
Coloplast lowered its 2030 growth ambition, citing US biologics reimbursement changes, pricing pressure and inflation. It expects biologics to return to growth in 2026/27 and said a resource reallocation program will support increased investment, with full benefits expected in 2027/28.
1. Growth ambition lowered
Coloplast lowered its 2030 growth ambition in its 2025/26 annual report, reflecting US biologics reimbursement changes, pricing pressure and inflation. Strong Chronic Care demand supported performance, while China remained weak and Men's Health drove growth in Interventional Urology.
2. Biologics and investment
US outpatient reimbursement changes disrupted Kerecis sales, prompting a sharper focus on inpatient care and a reduced outpatient organization. Coloplast expects biologics to return to growth in 2026/27. A resource reallocation program will fund increased investment in innovation and commercial expansion, with full benefits expected in 2027/28.
